|
[Related PubMed/MEDLINE]
Total Number of Papers: 1088
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: LMP1 |
| Long Form |
: latent membrane protein 1 |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A central role of IKK2 and TPL2 in JNK activation and viral B-cell transformation. |
EBV, IKK2, JNK, TAK1, Tpl2 |
| 2 |
2020 |
Capn4 is induced by and required for Epstein-Barr virus latent membrane protein 1 promotion of nasopharyngeal carcinoma metastasis through ERK/AP-1 signaling. |
CTAR, NPC |
| 3 |
2020 |
Carboxyl terminal activating region 3 of latent membrane protein 1 encoded by the Epstein‑Barr virus regulates cell proliferation and protein expression in NP69 cells. |
CTAR3, JAK3 |
| 4 |
2020 |
CD47 Overexpression Is Associated with Epstein-Barr Virus Infection and Poor Prognosis in Patients with Nasopharyngeal Carcinoma. |
DFS, EBV, NPC, siRNA |
| 5 |
2020 |
Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance. |
Drp1, EBV, NPC |
| 6 |
2020 |
Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance. |
Drp1, EBV, NPC |
| 7 |
2020 |
Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival. |
DUSPs, EBV, ERK, LCLs, MAPKs |
| 8 |
2020 |
EBV-LMP1 induces APOBEC3s and mitochondrial DNA hypermutation in nasopharyngeal cancer. |
A3B, A3s, EBV, NPC |
| 9 |
2020 |
Epstein-Barr Virus LMP1 Promotes Syntenin-1- and Hrs-Induced Extracellular Vesicle Formation for Its Own Secretion To Increase Cell Proliferation and Migration. |
BioID, CHMPs, EBV, EVs |
| 10 |
2020 |
Epstein-Barr virus-encoded latent membrane protein 1 promotes extracellular vesicle secretion through syndecan-2 and synaptotagmin-like-4 in nasopharyngeal carcinoma cells. |
EBV, EVs, NF, NPC, SDC2, SYTL4 |
| 11 |
2020 |
Evaluation of the effect of 5-aminolevulinic acid hexyl ester (H-ALA) PDT on EBV LMP1 protein expression in human nasopharyngeal cells. |
EBV, NPC, PDT |
| 12 |
2020 |
Extracellular vesicle packaged LMP1-activated fibroblasts promote tumor progression via autophagy and stroma-tumor metabolism coupling. |
CAFs, EBV, EVs, NFs, NPC, RWE |
| 13 |
2020 |
Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. |
EBV, ER, HL, RS |
| 14 |
2020 |
LMP1 promotes nasopharyngeal carcinoma metastasis through NTRK2-mediated anoikis resistance. |
EBV, EMT, NPC |
| 15 |
2020 |
LMP1 Up-regulates Calreticulin to Induce Epithelial-mesenchymal Transition via TGF-beta/Smad3/NRP1 Pathway in Nasopharyngeal Carcinoma Cells. |
CRT, EMT, NPC, NRP-1 |
| 16 |
2020 |
LMP1-specific cytotoxic T cells for the treatment of EBV-related post-transplantation lymphoproliferative disorders. |
CIK, EBV-CTLs, PTLD |
| 17 |
2020 |
Oligomerization analysis as a tool to elucidate the mechanism of EBV latent membrane protein 1 inhibition by pentamidine. |
EBV |
| 18 |
2020 |
Overexpression of Semaphorin 3A is a Marker Associated with Poor Prognosis in Patients with Nasopharyngeal Carcinoma. |
NPC, Sema3A |
| 19 |
2020 |
Targeting EZH2 depletes LMP1-induced activated regulatory T cells enhancing antitumor immunity in nasopharyngeal carcinoma. |
aTregs, EBV, EZH2, NPC, TAA |
| 20 |
2020 |
The Anti-Apoptotic Role of EBV-LMP1 in Lymphoma Cells. |
Bcl-2, EBV, MDM2 |
| 21 |
2020 |
Toll-like receptor 3 (TLR3) functions as a pivotal target in latent membrane protein 1 (LMP1)-mediated nasopharyngeal carcinoma cell proliferation. |
EBV, KD, NPC, TLR3 |
| 22 |
2020 |
Translational genomics of nasopharyngeal cancer. |
EBV, NPC |
| 23 |
2020 |
Wild-type IDH2 contributes to Epstein-Barr virus-dependent metabolic alterations and tumorigenesis. |
2-HG, alpha-KG, ChIP, EBV, HNSCC, IDH2, PCR, VCA-IgA |
| 24 |
2019 |
ATR activated by EB virus facilitates chemotherapy resistance to cisplatin or 5-fluorouracil in human nasopharyngeal carcinoma. |
5-FU, ATM, Chk1, EBV, NPC, NPI |
| 25 |
2019 |
B1.12: a novel peptide interacting with the extracellular loop of the EBV oncoprotein LMP1. |
EBV |
| 26 |
2019 |
Cancer-Associated Fibroblasts in Undifferentiated Nasopharyngeal Carcinoma: A Putative Role for the EBV-Encoded Oncoprotein, LMP1. |
CAFs, EBV, NPC |
| 27 |
2019 |
Construction of Epstein-Bar virus cocktail peptide fused with Fcgamma of IgG: as a potential delivery system for vaccine development. |
EBV, GP |
| 28 |
2019 |
CRISPR/Cas9-mediated LMP1 knockout inhibits Epstein-Barr virus infection and nasopharyngeal carcinoma cell growth. |
EBV, eIF4E, NPC, RT-qPCR, sgRNA |
| 29 |
2019 |
Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma. |
CDK1, EBV, NNKTL |
| 30 |
2019 |
EBV LMP1 in Gingival Epithelium Potentially Contributes to Human Chronic Periodontitis via Inducible IL8 Production. |
CATR, EBV, ELISA, IBalpha, IL-8, NF-B |
| 31 |
2019 |
EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2. |
3'UTR, ABCs, BHRF1, COO, DLBCLs, GCBs, miR, PD-L1 |
| 32 |
2019 |
Efficient Epstein-Barr Virus Progeny Production Mediated by Cancer-Derived LMP1 and Virally-Encoded microRNAs. |
BAC, EBV, LMP1B95-8, miRNA, NPC |
| 33 |
2019 |
Epstein-Barr virus infection in gliomas. |
EBER, EBV, GBM, PCR |
| 34 |
2019 |
Epstein-Barr virus latent membrane protein 1 (LMP1) regulates the aldehyde dehydrogenase (ALDH) positive cell population in nasopharyngeal carcinoma cell lines. |
ALDH, ALDH1, CK19, CSCs, EBV, IHC, NPC |
| 35 |
2019 |
Epstein-Barr Virus Latent Membrane Protein 1 Regulates Host B Cell MicroRNA-155 and Its Target FOXO3a via PI3K p110alpha Activation. |
EBV, miRs, PTLD, SMI |
| 36 |
2019 |
Epstein-Barr Virus Latent Membrane Protein-1 Induces the Expression of SUMO-1 and SUMO-2/3 in LMP1-positive Lymphomas and Cells. |
--- |
| 37 |
2019 |
Epstein-Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed-Sternberg cells via the PI3K-AKT-mTOR pathway. |
APC, EBV, HL, HRS |
| 38 |
2019 |
Essential role of inverted repeat in Epstein-Barr virus IR-1 in B cell transformation; geographical variation of the viral genome. |
EBV, invR |
| 39 |
2019 |
Exosomal cyclophilin A as a novel noninvasive biomarker for Epstein-Barr virus associated nasopharyngeal carcinoma. |
CyPA, EBV, ELISA, NPC |
| 40 |
2019 |
F factor plasmid-mediated Epstein-Barr virus genome introduction establishes an EBV positive NPC cell model. |
EBERs, EBNA1, EBV, LMP2A, NPC, TEM |
| 41 |
2019 |
Fibronectin promotes nasopharyngeal cancer cell motility and proliferation. |
EBV, HIF-1alpha, NPC, TGF-beta1 |
| 42 |
2019 |
Follicular dendritic cells display microvesicle-associated LMP1 in reactive germinal centers of EBV+ classic Hodgkin lymphoma. |
cHL, EBER, EBV, FDCs, GC, MC, NS |
| 43 |
2019 |
Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type. |
CTL, EBNA1, EBV, NK, NKTCL |
| 44 |
2019 |
Inhibition of UCH-L1 Deubiquitinating Activity with Two Forms of LDN-57444 Has Anti-Invasive Effects in Metastatic Carcinoma Cells. |
DUB, EBV, ECV, LDN-POx, NP, OSCC, UCH-L1 |
| 45 |
2019 |
Insufficient PINX1 expression stimulates telomerase activation by direct inhibition of EBV LMP1-NF-kappaB axis during nasopharyngeal carcinoma development. |
ChIP, EBV, NPC |
| 46 |
2019 |
LMP1 expression in bone marrow trephines of patients with multiple myeloma confers a survival advantage. |
ALDH1, BM, EBV, MM |
| 47 |
2019 |
LMP1 gene detection using a capped gold nanowire array surface plasmon resonance sensor in a microfluidic chip. |
SPR |
| 48 |
2019 |
Overexpression of Epstein-Barr virus-encoded latent membrane protein-1 (LMP-1) in oral squamous cell carcinoma. |
EBV, OL, OSCC |
| 49 |
2019 |
p53, latent membrane protein 1, bcl-2, and prognosis in nasopharyngeal carcinoma: a meta-analysis. |
NPC, OR, RD |
| 50 |
2019 |
Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC-subtype diffuse large B-cell lymphoma. |
ABC, DLBCL, EBV, GC, PI3K, S1P |
| 51 |
2019 |
Targeting Exosomal EBV-LMP1 Transfer and miR-203 Expression via the NF-kappaB Pathway: The Therapeutic Role of Aspirin in NPC. |
EBV, EMT, exo-LMP1, exo-miR203, miR-203, NF-kappaB, NPC |
| 52 |
2019 |
Targeting trimeric transmembrane domain 5 of oncogenic latent membrane protein 1 using a computationally designed peptide. |
EBV |
| 53 |
2019 |
The Epstein-Barr Virus Oncoprotein, LMP1, Regulates the Function of SENP2, a SUMO-protease. |
EBV |
| 54 |
2019 |
The JAK inhibitor antcin H exhibits direct anticancer activity while enhancing chemotherapy against LMP1-expressed lymphoma. |
EBV, MTX, ZAA |
| 55 |
2019 |
Using glycyrrhizic acid to target sumoylation processes during Epstein-Barr virus latency. |
EBV |
| 56 |
2019 |
[Establishment of human B lymphocyte strain overexpressing Epstein-Barr virus latent membrane protein 1 (LMP1)]. |
--- |
| 57 |
2018 |
(-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves downregulation of latent membrane protein 1. |
EBV, EGCG |
| 58 |
2018 |
A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy. |
EBV, TCR |
| 59 |
2018 |
Activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated lipogenesis by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma. |
EBV, FASN, mTOR, NPC, siRNA, SREBP1 |
| 60 |
2018 |
Blockage of store-operated Ca2+ entry antagonizes Epstein-Barr virus-promoted angiogenesis by inhibiting Ca2+ signaling-regulated VEGF production in nasopharyngeal carcinoma. |
2-APB, EBV, EGF, ELISA, HUVECs, NPC, VEGF |
| 61 |
2018 |
Bystander inhibition of humoral immune responses by Epstein-Barr virus LMP1. |
AID, ASCs, EBV, GC, IDO1, WT |
| 62 |
2018 |
C-Terminal Farnesylation of UCH-L1 Plays a Role in Transport of Epstein-Barr Virus Primary Oncoprotein LMP1 to Exosomes. |
EBV, NPC, UCH-L1 |
| 63 |
2018 |
Epstein-Barr virus encoded latent membrane protein 1 suppresses necroptosis through targeting RIPK1/3 ubiquitination. |
CMV, EBV, HSV, RHIM, RIPK1 |
| 64 |
2018 |
Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. |
MS |
| 65 |
2018 |
Global Proteomic Changes Induced by the Epstein-Barr Virus Oncoproteins Latent Membrane Protein 1 and 2A. |
DUB, EBV, IPA |
| 66 |
2018 |
IL-2Ralpha up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer/T-cell lymphoma. |
IL-2R alpha, NKTCL |
| 67 |
2018 |
LIMD1 is induced by and required for LMP1 signaling, and protects EBV-transformed cells from DNA damage-induced cell death. |
DDR, EBV, LIMD1 |
| 68 |
2018 |
Modified Anoikis Assay That Functionally Segregates Epstein-Barr Virus LMP1 Strains into Two Groups. |
CTAR, EBV, NPC |
| 69 |
2018 |
Modulation of the tumor microenvironment by Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma. |
NPC |
| 70 |
2018 |
Molecular Grading of Oral Squamous Cell Carcinomas Infected with EBV |
EBNA-1, EBV, OSCCs, SCC |
| 71 |
2018 |
Molecular signature of Epstein-Barr virus infection in MS brain lesions. |
EBER-1, EBV |
| 72 |
2018 |
New Insights from Elucidating the Role of LMP1 in Nasopharyngeal Carcinoma. |
EBV, NPC |
| 73 |
2018 |
Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma. |
CR, EBV, ENKTCL |
| 74 |
2018 |
Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1. |
EBV, HIF-1alpha, PARP1, PARylation |
| 75 |
2018 |
Role of microRNAs and Exosomes in Helicobacter pylori and Epstein-Barr Virus Associated Gastric Cancers. |
CagA, EBV, H. pylori, miRNAs |
| 76 |
2018 |
Tetraspanin CD63 Bridges Autophagic and Endosomal Processes To Regulate Exosomal Secretion and Intracellular Signaling of Epstein-Barr Virus LMP1 |
EBV, EV, mTOR |
| 77 |
2018 |
The EBV-Encoded Oncoprotein, LMP1, Induces an Epithelial-to-Mesenchymal Transition (EMT) via Its CTAR1 Domain through Integrin-Mediated ERK-MAPK Signalling. |
EBV, EMT, ERK-MAPK, FAK, MDCK |
| 78 |
2018 |
Transmembrane Domains Mediate Intra- and Extracellular Trafficking of Epstein-Barr Virus Latent Membrane Protein 1. |
EVs |
| 79 |
2017 |
A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway. |
ADCC, CDC, EBV, IHC, NK, WB |
| 80 |
2017 |
Association of Epstein - Barr virus and breast cancer in Eritrea. |
EBER, EBV, ISH, LMP2a, PCR |
| 81 |
2017 |
CD63 Regulates Epstein-Barr Virus LMP1 Exosomal Packaging, Enhancement of Vesicle Production, and Noncanonical NF-kappaB Signaling. |
EBV, EVs, MAPK/ERK, MVBs |
| 82 |
2017 |
Characterization of a Suppressive Cis-acting Element in the Epstein-Barr Virus LMP1 Promoter. |
EBV |
| 83 |
2017 |
Differentiation-Dependent LMP1 Expression Is Required for Efficient Lytic Epstein-Barr Virus Reactivation in Epithelial Cells. |
EBV, IE, NPC, OHL, TPA |
| 84 |
2017 |
Disruption of direct 3D telomere-TRF2 interaction through two molecularly disparate mechanisms is a hallmark of primary Hodgkin and Reed-Sternberg cells. |
cHL, EBV, RS, TRF2 |
| 85 |
2017 |
EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas. |
EBV, GMP |
| 86 |
2017 |
EBV-Negative Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder with Marked Morphologic Pleomorphism and Pathogenic Mutations in ASXL1, BCOR, CDKN2A, NF1, and TP53. |
cHL, DLBCL, EBER, EBV, FISH, NGS, PTLDs, VOUS |
| 87 |
2017 |
Elimination of LMP1-expressing cells from a monolayer of gastric cancer AGS cells. |
EBV |
| 88 |
2017 |
Enhanced aerobic glycolysis of nasopharyngeal carcinoma cells by Epstein-Barr virus latent membrane protein 1. |
EBV, LDH, NPC, PDK1, PKM2 |
| 89 |
2017 |
Epstein Barr virus Latent Membrane Protein-1 enhances dendritic cell therapy lymph node migration, activation, and IL-12 secretion. |
Ad5, DC |
| 90 |
2017 |
Epstein-Barr Virus Induces Adhesion Receptor CD226 (DNAM-1) Expression during Primary B-Cell Transformation into Lymphoblastoid Cell Lines. |
EBV, LCLs |
| 91 |
2017 |
Epstein-Barr virus infection and breast invasive ductal carcinoma in Egyptian women: A single center experience. |
EBNA-1, EBV, IDC, IHC |
| 92 |
2017 |
Epstein-Barr virus latent membrane protein-1 up-regulates cytokines and correlates with older age and poorer prognosis in Hodgkin lymphoma. |
EBV, HL, IL, MIP |
| 93 |
2017 |
Epstein-Barr Virus LMP1-Mediated Oncogenicity. |
EBV |
| 94 |
2017 |
Epstein-Barr virus-encoded latent membrane protein 1 induces epithelial to mesenchymal transition by inducing V-set Ig domain containing 4 (VSIG4) expression via NF-kB in renal tubular epithelial HK-2cells. |
EBV, EMT, VSIG4 |
| 95 |
2017 |
Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Upregulates Glucose Transporter 1 Transcription via the mTORC1/NF-kappaB Signaling Pathways. |
CTAR2, EBV, GLUT1, NPC, NPE |
| 96 |
2017 |
Epstein-Barr virus-positive follicular lymphoma. |
EBV |
| 97 |
2017 |
Exome and genome sequencing of nasopharynx cancer identifies NF-kappaB pathway activating mutations. |
EBV, NPC, WES, WGS |
| 98 |
2017 |
Exposure to the Epstein-Barr Viral Antigen Latent Membrane Protein 1 Induces Myelin-Reactive Antibodies In Vivo. |
CNS, EBV, FDCs, MBP, MS |
| 99 |
2017 |
Expression of interferon regulatory factor 7 correlates with the expression of Epstein-Barr Virus latent membrane protein 1 and cervical lymph node metastasis in nasopharyngeal cancer. |
EBV, IRF7, NPC |
| 100 |
2017 |
Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential. |
EBNA3A, EBV, LCLs |
|
A Search Service for Abbreviation / Long Form
